Drug Trial News

RSS

Lilly, Boehringer Ingelheim present full results of cardiovascular outcome trial, CARMELINA

Boehringer Ingelheim and Eli Lilly and Company today presented the full results of the long-term cardiovascular outcome trial, CARMELINA®, which studied the impact of Trajenta® (linagliptin) on cardiovascular and kidney safety in adults with type 2 diabetes at high risk for heart and/or kidney disease.

5 Oct 2018

Vaxart to present new data from Phase 2 Challenge Study of H1 influenza oral tablet vaccine

Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced it will present new data from the Phase 2 Challenge Study of its H1 influenza oral tablet vaccine at IDWeek 2018 in San Francisco on Saturday, October 6, 2018.

4 Oct 2018

Genentech announces Phase III study results of baloxavir marboxil in people at high risk of flu

Genentech, a member of the Roche Group, today announced that the Phase III CAPSTONE-2 study showed treatment with baloxavir marboxil significantly reduced the time to improvement of influenza symptoms versus placebo in people at high risk of serious complications from the flu, which includes adults 65 years of age or older, or those who have conditions such as asthma, chronic lung disease, morbid obesity, or heart disease.

4 Oct 2018

RCIGM and IDbyDNA launch clinical trial to improve diagnostics for pediatric CNS infections

The Rady Children's Institute for Genomic Medicine and IDbyDNA, a metagenomics technology company translating microbial genomics into actionable information for healthcare providers, have launched a clinical trial to improve diagnostics for pediatric central nervous system infections.

3 Oct 2018

Genentech announces clinical data from studies investigating risdiplam in spinal muscular atrophy

Genentech, a member of the Roche Group, announced today interim clinical data from the dose-finding parts of the pivotal FIREFISH and SUNFISH studies investigating risdiplam in spinal muscular atrophy.

3 Oct 2018

Alnylam submits CTA application to MHRA to initiate Phase 1/2 study of ALN-AAT02

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that it has submitted a Clinical Trial Authorization application to the Medicines and Healthcare products Regulatory Agency to initiate a Phase 1/2 study of ALN-AAT02, an investigational RNAi therapeutic targeting alpha-1 antitrypsin for the treatment of AAT deficiency-associated liver disease.

3 Oct 2018

Human clinical trial of investigational calcification inhibitor generates promising results

Cardiovascular calcification is a major health concern in patients with kidney failure undergoing hemodialysis.

3 Oct 2018

Scientists perform successful trial of new antibiotic on cancer reoccurrence after surgery

SCIENTISTS fighting cancer have carried out the first successful trial of the effects of the antibiotic Doxycycline on cancer reoccurrence in patients after surgery.

3 Oct 2018

Alnylam reports further progress on broadening the therapeutic potential of RNAi

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today further progress on the Company's platform efforts in extrahepatic delivery of novel siRNA conjugates, including central nervous system (CNS) and ocular delivery in rat and non-human primates (NHPs).

3 Oct 2018

Cancer drug trials focus on progression-free survival and overlook health-related quality of life

A McMaster University-led review and analysis of randomized clinical trials is questioning whether interventions which prolong progression-free survival in cancer patients, improve their health-related quality of life.

1 Oct 2018

Study using DFMO shows positive results for children with high risk neuroblastoma

A paper published September 27 in Scientific Reports shows the positive results of a phase II clinical trial using the oral medication DFMO to prevent relapse in children with High Risk Neuroblastoma.

1 Oct 2018

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited announced today that the phase 3 ECHELON-2 clinical trial met its primary endpoint.

1 Oct 2018

Gangrene-causing bacteria show promise as cancer treatment

Researchers have found that the bacteria responsible for causing gangrene could also be used to treat patients with certain cancers.

1 Oct 2018

$Bacterial therapy shows early clinical efficacy in patients with treatment-refractory solid tumors$

Bacterial therapy shows early clinical efficacy in patients with treatment-refractory solid tumors

A phase I clinical trial investigating the use of bacterial Clostridium novyi-NT spores as an injectable monotherapy had manageable toxicities and showed early clinical efficacy in patients with treatment-refractory solid tumor malignancies, according to data presented at the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, held Sept. 30-Oct. 3.

30 Sep 2018

Promising vaccine may provide new treatment option for patients with HER2-positive cancers

Treatment with a HER2-targeted therapeutic cancer vaccine provided clinical benefit to several patients with metastatic HER2-positive cancers who had not previously been treated with a HER2-targeted therapeutic, according to data from a phase I clinical trial presented at the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, held Sept. 30-Oct. 3.

30 Sep 2018

New combination therapy shows potential in treating incurable HPV-related cancers

A tumor-specific vaccine combined with an immune checkpoint inhibitor shrank tumors in one third of patients with incurable cancer related to the human papilloma virus (HPV) in a phase II clinical trial led by investigators at The University of Texas MD Anderson Cancer Center and reported in JAMA Oncology.

28 Sep 2018

Non-small cell lung cancer patients survive longer when treated with durvalumab

Non-small cell lung cancer patients survive longer when their treatment includes durvalumab following platinum-based chemoradiotherapy, according to research led by Moffitt Cancer Center.

27 Sep 2018

Cidara initiates Phase 3 clinical trial to evaluate efficacy, safety of rezafungin to treat invasive candidiasis

Cidara Therapeutics, Inc., a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the first trial site has been activated for ReSTORE, a Phase 3 clinical trial evaluating the efficacy and safety of the company's lead antifungal, rezafungin, to treat candidemia and invasive candidiasis.

27 Sep 2018

FLX Bio treats first patient in its Phase 1/2 clinical trial of FLX475 for treating various advanced cancers

FLX Bio, Inc., a clinical-stage, biopharmaceutical company focused on the development of oral small-molecule drugs that target drivers of cancer and other immune-related disorders, today announced that the first patient has been treated in its Phase 1/2 clinical trial of FLX475 in patients with various advanced cancers. FLX475 is an oral, small molecule CCR4 antagonist that selectively inhibits migration of regulatory T cells into the tumor microenvironment.

27 Sep 2018

CytoSen receives favorable response from FDA to its pre-IND meeting package for CSTD002-NK

CytoSen Therapeutics, a private biopharmaceutical company accelerating innovation in Natural Killer cell therapy, today announced it has received a favorable response from the U.S. Food and Drug Administration to its pre-Investigational New Drug meeting package for the proposed Phase 2 trial of CytoSen's adoptive NK cell therapy, CSTD002-NK, for the reduction of relapse in high risk acute myeloid leukemia or myelodysplastic syndrome in patients undergoing haploidentical hematopoietic stem cell transplantation.

27 Sep 2018

Drug Trial News

Lilly, Boehringer Ingelheim present full results of cardiovascular outcome trial, CARMELINA

Vaxart to present new data from Phase 2 Challenge Study of H1 influenza oral tablet vaccine

Genentech announces Phase III study results of baloxavir marboxil in people at high risk of flu

RCIGM and IDbyDNA launch clinical trial to improve diagnostics for pediatric CNS infections

Genentech announces clinical data from studies investigating risdiplam in spinal muscular atrophy

Alnylam submits CTA application to MHRA to initiate Phase 1/2 study of ALN-AAT02

Human clinical trial of investigational calcification inhibitor generates promising results

Scientists perform successful trial of new antibiotic on cancer reoccurrence after surgery

Alnylam reports further progress on broadening the therapeutic potential of RNAi

Cancer drug trials focus on progression-free survival and overlook health-related quality of life

Study using DFMO shows positive results for children with high risk neuroblastoma

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Gangrene-causing bacteria show promise as cancer treatment

Bacterial therapy shows early clinical efficacy in patients with treatment-refractory solid tumors

Promising vaccine may provide new treatment option for patients with HER2-positive cancers

New combination therapy shows potential in treating incurable HPV-related cancers

Non-small cell lung cancer patients survive longer when treated with durvalumab

Cidara initiates Phase 3 clinical trial to evaluate efficacy, safety of rezafungin to treat invasive candidiasis

FLX Bio treats first patient in its Phase 1/2 clinical trial of FLX475 for treating various advanced cancers

CytoSen receives favorable response from FDA to its pre-IND meeting package for CSTD002-NK

Unlocking live single-cell functional insights

Fluidics in Modern Healthcare & Medical Device Innovation

How microRNA is transforming science: From discovery to diagnostics

Latest News